PMID- 27443848 OWN - NLM STAT- MEDLINE DCOM- 20170619 LR - 20180301 IS - 1537-2995 (Electronic) IS - 0041-1132 (Linking) VI - 56 IP - 9 DP - 2016 Sep TI - Riboflavin and ultraviolet illumination affects selected platelet mRNA transcript amounts differently. PG - 2286-95 LID - 10.1111/trf.13715 [doi] AB - BACKGROUND: Pathogen inactivation (PI) techniques use ultraviolet (UV) illumination with or without a photosensitizer to destroy pathogen RNA and DNA. Although lacking a nucleus and innate DNA transcription, platelets (PLTs) contain RNA and can synthesize proteins. The impact of PI on PLT protein synthesis and function is unknown; altered synthesis may affect overall PLT quality. In this study we determine to what extent PLT RNA is affected by PI. STUDY DESIGN AND METHODS: In a pool-and-split design, paired apheresis PLT concentrates were treated with riboflavin and UV illumination or were left untreated. PLT total RNA and mRNA amounts specific for glycoproteins (GP)IIIa, GPIIb, and GPIb; alpha-granule proteins PLT factor (PF)4; osteonectin and thrombospondin (TSP); and housekeeping protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were determined using absorbance and quantitative polymerase chain reaction. RESULTS: After treatment, amounts of all analyzed mRNAs were significantly reduced (p < 0.05), but to different degrees. For GAPDH and PF4, transcripts appeared less susceptible to the treatment, with 70% remaining 1 hour after UV illumination. For GPIIIa and TSP, less than 15% remained after treatment. There was a correlation (R(2) = 0.85) between transcript length and amount of mRNA remaining 1 hour after treatment. Total RNA demonstrated a life span equal to the PLT life span of 10 to 11 days. CONCLUSION: This is the first report of the impact of riboflavin and UV illumination on PLT mRNA. Results suggest that all mRNA present in PLTs is affected by the treatment although the degree of the effect varies among transcripts. CI - (c) 2016 AABB. FAU - Klein-Bosgoed, Christa AU - Klein-Bosgoed C AD - Department of Pathology and Laboratory Medicine and Centre for Blood Research, University of British Columbia. FAU - Schubert, Peter AU - Schubert P AD - Department of Pathology and Laboratory Medicine and Centre for Blood Research, University of British Columbia. AD - Canadian Blood Services Centre for Innovation, Vancouver, BC, Canada. FAU - Devine, Dana V AU - Devine DV AD - Department of Pathology and Laboratory Medicine and Centre for Blood Research, University of British Columbia. dana.devine@blood.ca. AD - Canadian Blood Services Centre for Innovation, Vancouver, BC, Canada.. dana.devine@blood.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160721 PL - United States TA - Transfusion JT - Transfusion JID - 0417360 RN - 0 (Integrin beta3) RN - 0 (Osteonectin) RN - 0 (Platelet Membrane Glycoprotein IIb) RN - 0 (RNA, Messenger) RN - 0 (Thrombospondins) RN - 37270-94-3 (Platelet Factor 4) RN - EC 1.2.1.12 (Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)) RN - TLM2976OFR (Riboflavin) SB - IM MH - Blood Platelets/drug effects/*metabolism/radiation effects MH - Blood Preservation/methods MH - Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/analysis/genetics MH - Humans MH - Integrin beta3/analysis/genetics MH - Osteonectin/analysis/genetics MH - Platelet Factor 4/analysis/genetics MH - Platelet Membrane Glycoprotein IIb/analysis/genetics MH - RNA, Messenger/drug effects/*genetics/radiation effects MH - Riboflavin/*pharmacology MH - Thrombospondins/analysis/genetics MH - *Ultraviolet Rays EDAT- 2016/07/23 06:00 MHDA- 2017/06/20 06:00 CRDT- 2016/07/23 06:00 PHST- 2016/01/29 00:00 [received] PHST- 2016/05/17 00:00 [revised] PHST- 2016/05/31 00:00 [accepted] PHST- 2016/07/23 06:00 [entrez] PHST- 2016/07/23 06:00 [pubmed] PHST- 2017/06/20 06:00 [medline] AID - 10.1111/trf.13715 [doi] PST - ppublish SO - Transfusion. 2016 Sep;56(9):2286-95. doi: 10.1111/trf.13715. Epub 2016 Jul 21.